Traditional medicines have become the most productive source of leads for drugs development, particularly as anti-cancer agents. Various screening approaches are being applied. Sorafenib, a multikinase inhibitor, is used to treat primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer. A small library of compounds analogous to sorafenib were designed and screened for the treatment of liver cancer. Multiple members of the family in an assay panel of tyrosine kinase family and serine/threonine-protein kinase family, including VEGFR, Abl, Aurora A, p 38, Lck, Src, PDGFR, Flt3, c-RAF, c-KIT, MEK(MAPKK) were selected to test these compounds. Analysis of the selectivity patterns for these compounds shows specificity for many kinase families. IC 50 were measured for the selected compounds.
Introduction
Traditional medicines have become the most productive source of leads for drugs development, particularly as anti-cancer agents. Combinatorial chemistry approaches are being based on the scaffolds of traditional and alternative medicines to create screening libraries that closely resemble drug-like compounds. Various screening approaches are being developed and data mining and virtual screening techniques are being applied. At the present time, sorafenib approved by the FDA in 2005, is a multikinase inhibitor, targeting several serine/threonine and receptor tyrosine kinases (RAF kinase, VEGFR-2,VEGFR-3, PDGFR-beta, KIT, and FLT-3) (Hu et al., 2011) . Sorafenib, is used to treat primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). At the onset of the medicinal chemistry programme that led to sorafenib, there were no marketed kinase inhibitors in the field of oncology. However, before the approval of sorafenib, two first-generation targeted anticancer agents -Gleevec (Novartis) and Tarceva (Genentech), which target Bcr-Abl and EGFR, respectively -had begun to show clinical benefit (Capdeville et al., 2002) , (Dowell et al., 2005) In multiple clinical trials, sorafenib is as both combination and single-agent therapies.
Analysis of newly introduced drugs states that sorafenib has reached the market from an origin in high-throughput screening of combinatorial chemistry libraries. Tyrosine kinase inhibitor was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients (Feng et al., 2009) . Some drug has clinical toxicity and exerted its hepatotoxicity via both hepatocellular injury and hepatobiliary cholestatic mechanisms. The direct cytotoxic effect, hepatobiliary disposition and inhibition of active canalicular transport of bile constituents have been evaluated in established human hepatocyte models and in vitro transporter systems. The major human hepatic uptake transporter, multidrug resistance protein 1 (MDR1) and breast cancer resistance protein, was involved in hepatobiliary clearance. Evidence suggests three major mechanisms of medicine used clinically for the treatment of cholestatic liver diseases: (1) Tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell (Stepanek et al., 2011) . It functions as an "on" or "off" switch in many cellular functions. Receptor tyrosine kinases (RTK) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Of the 90 unique tyrosine kinase genes identified in the human genome, 58 encode receptor tyrosine kinase proteins. (Robinson et al., 2000) This gene encodes a member of the Ser/Thr protein kinase family. This kinase is regulated through direct phosphorylation by p38 MAP kinase. In conjunction with p38 MAP kinase, this kinase is known to be involved in many cellular processes including stress and inflammatory responses. The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase.
Serine/threonine-protein kinases select specific residues to phosphorylate on the basis of residues that flank the phosphoacceptor site, which together comprise the consensus sequence. Aurora A kinase known as serine/threonine-protein kinase 6 is an enzyme that in humans is encoded by the AURKA gene.
Methods
We have recently disclosed a novel series of compounds as inhibitors of tyrosine kinases serine/threonine-protein kinases based on the source of traditional medicines. A minimized binding mode of the ATP pocket of the ligand-binding Pocket model is shown in Figure 1 . A limited set of small hydrophobic groups may be substituted on this phenyl ring at very specific positions since the pocket possesses a limited tolerance for larger groups (Figure 1 ). The sketch of the components of the library and synthesis scheme is shown in Figure 2 .
Based on the scaffold from nature products, we synthesized 50 compounds with the R1, R2 resion sit for the pocket. A small library of compounds analogous to sorafenib were designed and screened against multiple members of the tyrosine kinase and serine/threonine-protein kinase. To determine the kinase profiler and IC 50 profiler, the reference inhibitor control compounds have been introduced in the kinase profiler and IC 50 profiler express operational procedure. The structure of the tested compounds is shown in Table 1 . Some tyrosine kinase and serine/threonine-protein kinase were selected to test the kinase profiler and IC 50 (Table 2) . 
Kinase Profiler and IC 50 Profiler
A family of validated kinase targets was identified with specific structural features. The composition of the dilution buffer for each kinase is shown in Table 3 . All kinases are pre-diluted to a 10x working concentration prior to addition into the assay. The Kinase Profiler of ATP concentration is shown in Table 4 . 
Lck
In a final reaction volume of 25 μl, Lck (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 250 μM KVEKIGEGTYGVVYK (Cdc2 peptide), 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.
MEK1
In a final reaction volume of 25 μl, MEK1 (1-5 mU) is incubated with 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% β-mercaptoethanol, 0.01% Brij-35, 1 μM inactive MAPK2 (m), 10 mM MgAcetate and cold ATP (concentration as required).
The reaction is initiated by the addition of the MgATP. After incubation for 40 minutes at room temperature, 5 μl of this incubation mix is used to initiate a MAPK2 (m) assay, which is described on page 12 of this book.
PDGFR
In a final reaction volume of 25 μl, PDGFRα (5-10 mU) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1 mg/ml poly (Glu, Tyr) 4:1, 10 mM MnCl2, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol,
